Literature DB >> 7000632

Defective opsonisation and complement deficiency in serum from patients with fulminant hepatic failure.

R J Wyke, I A Rajkovic, A L Eddleston, R Williams.   

Abstract

Serum from 23 of 26 patients with fulminant hepatic failure and grade IV encephalopathy had defective opsonisation of E. coli and yeast (S. cerevisiae). No toxic serum factors acting on the polymorphonuclear leucocytes or inactivators of the normal serum opsonisation factors were found. Complement deficiency was shown to be the most likely cause of the defect in opsonisation. The addition of a heat-labile fraction of normal serum at low concentration corrected the defect and factors of both the classical and the alternative pathways of complement were reduced to below 40% of the activity of the control serum. During the early stages of clinical recovery serum opsonisation and complement activity returned to normal with statistically significant correlations between tests of opsonisation and total haemolytic complement CH50, C3 and total alternative pathway activity. Defective serum opsonisation and complement deficiency represent major defects in the body's defences against infection.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7000632      PMCID: PMC1419118          DOI: 10.1136/gut.21.8.643

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  18 in total

1.  Total haemolytic complement after liver transplantation and in liver disease.

Authors:  A P Pagaltsos; M G Smith; A L Eddleston; R Williams
Journal:  Transplantation       Date:  1972-07       Impact factor: 4.939

2.  Phagocytosis as a surface phenomenon. II. Contact angles and phagocytosis of encapsulated bacteria before and after opsonization by specific antiserum and complement.

Authors:  C J Van Oss; C F Gillman
Journal:  J Reticuloendothel Soc       Date:  1972-11

3.  Homozygous deficiency of C3 in a patient with repeated infections.

Authors:  C A Alper; H R Colten; F S Rosen; A R Rabson; G M Macnab; J S Gear
Journal:  Lancet       Date:  1972-12-02       Impact factor: 79.321

4.  Microbiological monitoring of patients in hepatic failure with particular reference to extracorporeal porcine liver perfusion.

Authors:  R V Mummery; J M Bradley; D J Jeffries
Journal:  Lancet       Date:  1971-07-10       Impact factor: 79.321

5.  Complement and liver cell function in 53 patients with liver disease.

Authors:  O Kourilsky; C Leroy; A P Peltier
Journal:  Am J Med       Date:  1973-12       Impact factor: 4.965

6.  Metabolic inhibition of polymorphonuclear leucocytes in fulminant hepatic failure.

Authors:  R J Bailey; I L Woolf; H Cullens; R Williams
Journal:  Lancet       Date:  1976-05-29       Impact factor: 79.321

7.  Deficiency of C3 inactivator in man.

Authors:  N Abramson; C A Alper; P J Lachmann; F S Rosen; J H Jandl
Journal:  J Immunol       Date:  1971-07       Impact factor: 5.422

8.  Causes of death in fulminant hepatic failure and relationship to quantitative histological assessment of parenchymal damage.

Authors:  B G Gazzard; B Portmann; I M Murray-Lyon; R Williams
Journal:  Q J Med       Date:  1975-10

9.  Serum heat-labile opsonins in systemic lupus erythematosus.

Authors:  H E Jasin; J H Orozco; M Ziff
Journal:  J Clin Invest       Date:  1974-02       Impact factor: 14.808

10.  In vitro bactericidal capacity of human polymorphonuclear leukocytes: diminished activity in chronic granulomatous disease of childhood.

Authors:  P G Quie; J G White; B Holmes; R A Good
Journal:  J Clin Invest       Date:  1967-04       Impact factor: 14.808

View more
  21 in total

Review 1.  Infections.

Authors:  N Rolando; R J Wyke
Journal:  Gut       Date:  1991-09       Impact factor: 23.059

2.  Neutrophil activation during acetaminophen hepatotoxicity and repair in mice and humans.

Authors:  C David Williams; Mary Lynn Bajt; Matthew R Sharpe; Mitchell R McGill; Anwar Farhood; Hartmut Jaeschke
Journal:  Toxicol Appl Pharmacol       Date:  2014-01-15       Impact factor: 4.219

Review 3.  Problems of bacterial infection in patients with liver disease.

Authors:  R J Wyke
Journal:  Gut       Date:  1987-05       Impact factor: 23.059

4.  Impaired opsonization by serum from patients with chronic liver disease.

Authors:  R J Wyke; I A Rajkovic; R Williams
Journal:  Clin Exp Immunol       Date:  1983-01       Impact factor: 4.330

5.  Early diagnosis of bacterial and fungal infection in chronic cholestatic hepatitis B.

Authors:  Xiong-Zhi Wu; Dan Chen; Lian-San Zhao; Xiao-Hui Yu; Mei Wei; Yan Zhao; Qing Fang; Qian Xu
Journal:  World J Gastroenterol       Date:  2004-08-01       Impact factor: 5.742

Review 6.  Role of inflammation and infection in the pathogenesis of human acute liver failure: Clinical implications for monitoring and therapy.

Authors:  Mhairi C Donnelly; Peter C Hayes; Kenneth J Simpson
Journal:  World J Gastroenterol       Date:  2016-07-14       Impact factor: 5.742

7.  Neutrophil adherence in chronic liver disease and fulminant hepatic failure.

Authors:  M Altin; I A Rajkovic; R D Hughes; R Williams
Journal:  Gut       Date:  1983-08       Impact factor: 23.059

8.  Monocyte function in cirrhosis.

Authors:  G Holdstock; B Leslie; S Hill; A Tanner; R Wright
Journal:  J Clin Pathol       Date:  1982-09       Impact factor: 3.411

9.  Unusual case of Aeromonas hydrophila endocarditis.

Authors:  K R Ong; E Sordillo; E Frankel
Journal:  J Clin Microbiol       Date:  1991-05       Impact factor: 5.948

10.  Serum stimulatory activity and polymorphonuclear leucocyte movement in patients with fulminant hepatic failure.

Authors:  R J Wyke; A G Yousif-Kadaru; I A Rajkovic; A L Eddleston; R Williams
Journal:  Clin Exp Immunol       Date:  1982-11       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.